CN114252548A - Method for simultaneously detecting multiple components in large seven-li preparation - Google Patents
Method for simultaneously detecting multiple components in large seven-li preparation Download PDFInfo
- Publication number
- CN114252548A CN114252548A CN202210194754.XA CN202210194754A CN114252548A CN 114252548 A CN114252548 A CN 114252548A CN 202210194754 A CN202210194754 A CN 202210194754A CN 114252548 A CN114252548 A CN 114252548A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- preparation
- acid
- carbonyl
- multiple components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- ZPFRAPVRYLGYEC-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)propan-1-one Chemical compound COC1=CC(OC)=CC(OC)=C1CCC(=O)C1=CC=C(O)C=C1 ZPFRAPVRYLGYEC-UHFFFAOYSA-N 0.000 claims abstract description 72
- 238000001514 detection method Methods 0.000 claims abstract description 48
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 claims abstract description 47
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 claims abstract description 47
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000243 solution Substances 0.000 claims abstract description 43
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 claims abstract description 37
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 claims abstract description 37
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 claims abstract description 30
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 18
- GKAJCVFOJGXVIA-JRSUCEMESA-N Rhapontin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]3O)c2)cc1O GKAJCVFOJGXVIA-JRSUCEMESA-N 0.000 claims abstract description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000012088 reference solution Substances 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019253 formic acid Nutrition 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- 238000005303 weighing Methods 0.000 claims description 26
- 240000007551 Boswellia serrata Species 0.000 claims description 19
- 238000000862 absorption spectrum Methods 0.000 claims description 15
- 239000012085 test solution Substances 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 235000018062 Boswellia Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000000527 sonication Methods 0.000 claims 1
- 239000013558 reference substance Substances 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000926 separation method Methods 0.000 abstract description 10
- 230000001788 irregular Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 37
- 239000009136 dragon's blood Substances 0.000 description 18
- 239000004863 Frankincense Substances 0.000 description 15
- 235000003717 Boswellia sacra Nutrition 0.000 description 14
- 235000012035 Boswellia serrata Nutrition 0.000 description 14
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 12
- 241000219061 Rheum Species 0.000 description 9
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 240000004980 Rheum officinale Species 0.000 description 8
- 235000008081 Rheum officinale Nutrition 0.000 description 8
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 8
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 240000004824 Trimezia steyermarkii Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004634 feeding behavior Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 3
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 3
- 240000007311 Commiphora myrrha Species 0.000 description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000008090 Rheum palmatum Nutrition 0.000 description 2
- 240000001745 Rheum palmatum Species 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229930192497 loureirin Natural products 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000219053 Rumex Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention belongs to the field of quality detection of traditional Chinese medicines, and particularly relates to a method for simultaneously detecting multiple components in a large seven centimetre preparation, which adopts an HPLC method to respectively carry out content determination and result judgment on a mixed reference substance solution and a test substance solution, uses octadecylsilane chemically bonded silica as a chromatographic column filler, uses acetonitrile as a mobile phase A and a 0.1% formic acid solution as a mobile phase B to carry out gradient elution, and the number of theoretical plates is not less than 4000 according to the calculation of a rhapontin peak; the reference solution contains abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid. The method for simultaneously detecting the multiple components in the large seven centimetre preparation is established, has the advantages of good separation effect, good repeatability, low detection limit, rapidness, accuracy, simplicity, convenience, high efficiency and low cost, and can be used as a technical means for controlling the irregular feeding of the large seven centimetre preparation in adulteration.
Description
Technical Field
The invention belongs to the field of quality detection of traditional Chinese medicines, and particularly relates to a method for simultaneously detecting multiple components in a large seven-centimeter preparation.
Background
The preparation comprises four dosage forms of DAQILI powder, DAQILI tablet, DAQILI Capsule and DAQILI pill, and the prescription comprises radix et rhizoma Rhei, sanguis Draxonis, Olibanum, Myrrha, Eupolyphaga Seu Steleophaga, Pyritum, rhizoma Drynariae, radix Angelicae sinensis tail, Borax, Notoginseng radix and Borneolum Syntheticum, and is prepared from raw powder. In recent years, driven by commercial interest, many counterfeit traditional Chinese medicines appear in the market, wherein the counterfeit traditional Chinese medicines are rhubarb with large use amount and wide use range, and frankincense, myrrh and dragon blood which are consistently imported and lack of medicines in history. The dry roots and rhizomes of Rheum palmatum L., Rheum tanguticum Maxim. or Rheum officinale Baill. of Polygonaceae are certified Rheum officinale prescribed in Chinese pharmacopoeia, while Rheum palmatum L., Rheum tanguticum Maxim. and the like of the same genus of Rheum are counterfeit Rheum officinale, which are low in price and are often used as certified Rheum officinale in the market. Research shows that the genuine rhubarb does not contain rhapontin, while the counterfeit rhubarb contains rhapontin, in the thin-layer chromatography inspection of the genuine rhubarb in the 2020 edition of Chinese pharmacopoeia, the rhapontin is required not to be detected and is a characteristic component which is different from the genuine rhubarb. The dragon blood is an important south medicine, is always imported historically, is one of medicinal materials in short supply in China, and is extremely similar to the dragon blood in appearance characteristics such as color, texture and the like, so that the dragon blood is frequently used as the dragon blood or doped in the market, and certain difficulties are brought to the correct use, daily inspection and supervision of the drug administration product. The research shows that the chemical components of the dragon blood and the dragon blood are different to a certain extent, wherein the dracorhodin A and the dracorhodin B mainly exist in the dragon blood, the dracorhodin B is the effective component of the dragon blood, and the dragon blood mainly contains components such as dracorhodin and the like and does not contain the dracorhodin B, so the dracorhodin B can be used as the characteristic component for distinguishing the dragon blood and the dragon blood. The frankincense, the myrrh and the dragon's blood are all resin medicinal materials, China mainly depends on import to meet the domestic medicine demand, due to the increase of the medicine dosage, the source is limited, the price is high, pseudo inferior products often appear on the market, and market investigation shows that the rosin is used as a main raw material to be processed into pseudo products or adulterated products with different specifications so as to gain violence. Rosin is a transparent solid obtained after distillation of pine resin and is used as an industrial raw material, the main component is organic acid, wherein the content of rosin acid is very high and is about 35-60%, the rosin acid belongs to terpenoid and is low in toxicity and has great harm to human health, and due to large price difference, rosin adulteration phenomenon exists in frankincense, myrrh and dragon blood, and the rosin acid can be used as a detection index for identifying whether rosin is adulterated. The frankincense acid in the frankincense is a main effective component for resisting inflammation, easing pain and resisting immunity, particularly the 11-carbonyl-beta-acetyl frankincense acid is a main component for the frankincense to play a role of activating blood and relieving pain, and as the frankincense medicinal materials are high in market price, in order to save cost, the situation that the frankincense is fed out according to requirements frequently occurs in production, and the feeding situation of the frankincense can be effectively monitored by taking the 11-carbonyl-beta-acetyl frankincense acid as a detection index.
The Da Qili preparation has the effects of removing blood stasis, relieving swelling, relieving pain and stopping bleeding, and is mainly used for treating traumatic injury, blood stasis and pain, traumatic bleeding stopping and other diseases. Although the existing standards of the four dosage forms of the big Qili powder, the big Qili tablet, the big Qili capsule and the big Qili pill are different, the quality control of the frankincense is not carried out, and the existing standard detection items have defects. Reports related to the quality research of the large seven centimetre preparation are few, and particularly, the research on the adulteration and non-standard feeding of the large seven centimetre preparation is not reported in documents. At present, for a sample adulterated with adulteration, the quality of the sample cannot be completely controlled and the condition of irregular feeding cannot be distinguished only according to the inspection item of the current standard of a big seven centi preparation. Therefore, it is necessary to research and establish a method for simultaneously detecting rhaponticin, loureirin B, abietic acid and 11-carbonyl-beta-acetyl boswellic acid by using an HPLC method as a technical means for controlling the adulteration and non-standard feeding of the rheum officinale formulation.
Disclosure of Invention
The invention aims to provide a brand new method for simultaneously detecting multiple components in a large seven centimetre preparation, the invention successfully establishes an HPLC method capable of simultaneously detecting abietic acid, rhapontin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid in the large seven centimetre preparation, the method can distinguish the nonstandard feeding condition of the sample in a forward and reverse combined mode by simultaneously detecting the adulterated product and the effective components in the sample, and check whether the sample is doped with rosin, the forged rhubarb, dragon's blood and frankincense, the method can save time and has low cost, and the high efficiency and the practicability of one-method multiple detection are reflected. The detection method can effectively make up the defects of the existing standard detection project of the large seven centi preparation, solve the problem of quality control blind spots, prevent the non-standard feeding behavior of adulteration and adulteration, and provide a new detection means for striking the non-standard feeding behavior of adulteration and adulteration.
The invention provides a brand-new method for simultaneously detecting multiple components in a large seven centimetre preparation, which adopts an HPLC method to respectively carry out content determination and result judgment on a mixed reference substance solution and a test substance solution, uses octadecylsilane chemically bonded silica as a chromatographic column filler, uses acetonitrile as a mobile phase A, uses a 0.1% formic acid solution as a mobile phase B, and carries out gradient elution, wherein the number of theoretical plates is not less than 4000 according to the calculation of a rhaponticin peak; the reference solution contains abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid.
The technical scheme successfully establishes a method for simultaneously detecting abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid in the large seven centimetre preparation by optimizing HPLC chromatographic conditions, the chromatographic peak separation of the method is good, the peak shapes are symmetrical, the raw material feeding of the large seven centimetre preparation is strictly controlled in a forward and reverse combined mode, the method is accurate and efficient, the method can effectively prevent the irregular feeding behavior of adulteration and adulteration, and makes up the defects of the existing standard detection project of the large seven centimetre preparation.
Further, in the above technical solution, in the gradient elution, the volume ratio of each time period and mobile phase is:
when the time is 0-10min, the volume ratio of the mobile phase A is increased from 15% to 35%, and the volume ratio of the mobile phase B is decreased from 85% to 65%;
when the time is 10-30min, the volume ratio of the mobile phase A is increased from 35% to 50%, and the volume ratio of the mobile phase B is decreased from 65% to 50%;
when the time is 30-55min, the volume ratio of the mobile phase A is increased from 50% to 90%, and the volume ratio of the mobile phase B is decreased from 50% to 10%;
when the time is 55-70min, the volume ratio of the mobile phase A is 90%, and the volume ratio of the mobile phase B is 10%.
Further, in the above technical solution, the detection wavelength of the HPLC is a segment wavelength, and the conversion manner of the segment wavelength is as follows: at 0-25min, the wavelength is 328 nm; the wavelength is 280nm when the time is 25-45 min; the wavelength is 241nm at 45-70 min.
In the technical scheme, due to the fact that ultraviolet absorption wavelengths of the abietic acid, the rhapontin, the loureirin B and the 11-carbonyl-beta-acetyl boswellic acid are different, in order to enable response values of all peaks to reach larger values, a detection wavelength conversion mode is adopted for detection.
Preferably, the column temperature in the HPLC method is 30 ℃ and the flow rate is 1.0 mL/min.
Further, in the above technical solution, the method for determining the result includes: (1) in the chromatogram of the test solution, the same chromatographic peak is not obtained at the position corresponding to the retention time of the chromatographic peak of the reference solution of abietic acid, rhapontin and lourerin B, and when the chromatographic peak with the same retention time is obtained, a diode array detector is adopted to compare the ultraviolet-visible absorption spectra of the corresponding chromatographic peak, and the absorption spectra are different; when the absorption spectra are the same, the detection result is regarded as positive detection; (2) the content of 11-carbonyl-beta-acetyl boswellic acid in the test solution is not less than 2.0mg/g, and when the detection result is less than 2.0mg/g, the boswellia is regarded as being not fed according to the prescription amount.
Further, in the above technical scheme, the preparation method of the mixed reference solution comprises precisely weighing appropriate amounts of the reference products abietic acid, rhapontin, loureirin B and 11-carbonyl- β -acetyl boswellic acid, placing into a volumetric flask, and adding methanol to prepare a mixed solution containing abietic acid, rhapontin, loureirin B and 11-carbonyl- β -acetyl boswellic acid, namely the mixed reference solution.
Further, in the above technical scheme, the preparation method of the test solution comprises precisely weighing a proper amount of the comminuted and uniformly mixed large seven centimetre preparation sample, placing the sample in a conical flask with a plug, precisely adding a methanol solution, sealing the plug, weighing, carrying out ultrasonic treatment for 30min, taking out, cooling, weighing again, complementing the lost weight with the methanol solution, shaking up, and filtering to obtain a subsequent filtrate, namely the test solution.
Further, in the above technical solution, the power of the ultrasonic treatment is 500W, and the frequency is 40 kHz.
Further, in the above technical scheme, the abietic acid, rhapontin and lourerin B are derived from non-standard feeding materials, and the 11-carbonyl-beta-acetyl boswellic acid is a prescription component of the big seven centi preparation. In the technical scheme, the rosin acid can be derived from rosin; the rhaponticin may be derived from pseudorheum officinale including radix et rhizoma Rhei Franzenbachii and radix et rhizoma Rhei Tianshan; the loureirin B may be from dragon's blood, but the above-mentioned materials are not the prescription components of big seven li preparation, after adding it, not only can reduce the dose of prescription components, but also can affect medicinal effect, and can bring about side effect. The 11-carbonyl-beta-acetyl boswellic acid is a prescription component of a large seven-centimeter preparation, namely an effective component of the boswellia, and if the boswellia is not fed according to the prescription amount, the efficacy of the boswellia is inevitably influenced. Therefore, the invention can be used for monitoring whether the rosin, the counterfeit rhubarb, the dragon's blood and the frankincense are mixed in the sample by simultaneously detecting the four components, and effectively preventing the phenomenon that the adulteration and the non-standard feeding are carried out.
Further, in the above technical scheme, the big qili preparation is any one of big qili tablets, big qili pills, big qili capsules and big qili powder.
The invention also provides an application of the method for simultaneously detecting the multiple components in the large seven-centimeter preparation in quality detection of the large seven-centimeter preparation.
Compared with the prior art, the method has the beneficial effects that:
1. the invention successfully establishes a method for simultaneously detecting abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid in the large seven centi preparation by optimizing HPLC chromatographic conditions, and the adopted chromatographic conditions have good separation effect, symmetrical peak shape, small interference, good repeatability of detection results and low detection limit.
2. The detection method can strictly control the raw material feeding of the large seven centimetre preparation in a forward and reverse combined mode, and can effectively prevent the phenomena of adulteration, less feeding and other irregular feeding.
3. The detection method is rapid, accurate, simple, convenient, efficient and low in cost, realizes one-method multi-detection, can effectively make up for the defects of the existing standard detection project of the large Qili preparation, solves the problem of the quality control blind spot of the large Qili preparation, and provides a new detection means for striking the non-standard feeding behavior of adulteration.
Drawings
FIG. 1 is a graph of the rhaponticin absorption spectrum of the present invention;
FIG. 2 is a diagram of the absorption spectrum of loureirin B according to the present invention;
FIG. 3 is a diagram showing an absorption spectrum of abietic acid according to the present invention;
FIG. 4 is an absorption spectrum of 11-carbonyl- β -acetyl boswellic acid according to the present invention;
FIG. 5 is an HPLC chromatogram of a mixed control according to the present invention;
FIG. 6 is an HPLC chromatogram of a rhaponticin reference substance of the present invention;
FIG. 7 is an HPLC chromatogram of a reference of loureirin B of the present invention;
FIG. 8 is an HPLC chromatogram of a rosin acid control reagent of the present invention;
FIG. 9 is an HPLC chromatogram of 11-carbonyl- β -acetyl boswellic acid control of the present invention;
FIG. 10 is an HPLC chromatogram of a large heptad sample (batch No. 200602) according to the present invention;
FIG. 11 is an HPLC chromatogram of a large Qili pill sample (lot: 20190601) according to the present invention;
FIG. 12 is an HPLC chromatogram of a large Qilisan sample (lot: 191101) according to the present invention;
FIG. 13 is an HPLC chromatogram of a large seven centimetre capsule sample (batch number: 01-200302) of the present invention.
Detailed Description
The technical features of the present invention described above and those described in detail below (as an embodiment) can be combined with each other to form a new or preferred technical solution, but the present invention is not limited to these embodiments, and the embodiments also do not limit the present invention in any way.
The experimental procedures in the following examples are conventional unless otherwise specified. The formulations according to the following examples are all commercially available products and are commercially available, unless otherwise specified.
The invention is described in further detail below with reference to the figures and examples:
experimental instruments and materials:
1. instrument for measuring the position of a moving object
Agilent model 1260 high performance liquid chromatograph (with DAD detector), Agilent chemStation for LC Systems chromatography workstation; CAPCELL PAK C18(250 mm. times.4.60 mm,5 μm) chromatography column.
A BT25S model sialus electronic balance, a ML204 model mettlerlitolpoly electronic balance, and a KQ-500E model ultrasonic cleaner.
2. Material
The abietic acid reference reagent (batch No. 111938-201902), the rhaponticin reference substance (batch No. 110794-201909), the loureirin B reference substance (batch No. 111558-200303) and the 11-carbonyl-beta-acetyl boswellic acid reference substance (batch No. 111760-201502) are purchased from China food and drug testing institute; acetonitrile is chromatographically pure, and other reagents are analytically pure.
Example 1: determination of chromatographic conditions and detection wavelengths
1. Preparation of the solution
1.1 preparation of Mixed control solutions
Accurately weighing appropriate amount of reference substances including abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid, placing into a volumetric flask, and adding methanol to obtain mixed solutions containing abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid of 3.8 μ g/mL, 10.06 μ g/mL, 10.0 μ g/mL and 3.972 μ g/mL respectively, to obtain mixed reference substance solution.
1.2 preparation of test solutions
Precisely weighing a proper amount of the grinded and uniformly mixed large seven centi preparation sample, placing the large seven centi preparation sample into a conical flask with a plug, precisely adding 25mL of methanol solution, sealing the plug, weighing, carrying out ultrasonic treatment for 30min, taking out, cooling, weighing again, complementing the lost weight with the methanol solution, shaking up, and filtering to obtain a subsequent filtrate, namely the test solution. Wherein 20 large Qili tablets are taken and ground into fine powder, and about 0.6g of the fine powder is taken; or grinding appropriate amount of DAQILI pill to obtain about 0.7 g; or grinding the content of DAQILI Capsule, collecting about 0.5g, or mixing with the content of DAQILI powder, collecting about 1g, precisely weighing, placing into conical flask with plug, precisely adding 25mL methanol, sealing, weighing, ultrasonic treating for 30min, taking out, cooling, weighing, supplementing the weight loss with methanol, shaking, filtering, and collecting the filtrate.
1.3 preparation of Single Standard reference solutions
Accurately weighing appropriate amount of reference substances including abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid, respectively placing into different volumetric flasks, and adding methanol to obtain single-standard reference substance solutions containing abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid of 3.8 μ g/mL, 18.95 μ g/mL, 68.9 μ g/mL and 8.04 μ g/mL respectively.
2. Chromatographic conditions
Octadecylsilane chemically bonded silica gel as filler, and CAPCELL PAK C as chromatographic column18(250 mm. times.4.60 mm,5 μm); acetonitrile is taken as a mobile phase A, and 0.1% formic acid solution is taken as a mobile phase B; performing gradient elution; detecting wavelength segments and carrying out wavelength conversion; the column temperature is 30 ℃, and the number of theoretical plates is not lower than 4000 according to the rhaponticin peak.
The gradient elution procedure was: when the time is 0-10min, the volume ratio of the mobile phase A is increased from 15% to 35%, and the volume ratio of the mobile phase B is decreased from 85% to 65%;
when the time is 10-30min, the volume ratio of the mobile phase A is increased from 35% to 50%, and the volume ratio of the mobile phase B is decreased from 65% to 50%;
when the time is 30-55min, the volume ratio of the mobile phase A is increased from 50% to 90%, and the volume ratio of the mobile phase B is decreased from 50% to 10%;
when the time is 55-70min, the volume ratio of the mobile phase A is 90%, and the volume ratio of the mobile phase B is 10%.
The detection wavelength is wavelength conversion in the following manner: at 0-25min, the wavelength is 328 nm; the wavelength is 280nm when the time is 25-45 min; the wavelength is 241nm at 45-70 min.
The sample injection amount is 10 mu L; the flow rate was 1.0 mL/min.
3. Condition optimization
3.1 selection of detection wavelength
Due to the complexity and diversity of the ingredients of traditional Chinese medicine, the ultraviolet absorption wavelengths of different chemical ingredients are different. Scanning ultraviolet absorption spectra of 4 component reference substances at 200-400 nm on a visible-ultraviolet spectrophotometer, wherein the maximum absorption wavelength of rhaponticin is 328nm, the maximum absorption wavelength of loureirin B is 280nm, the maximum absorption wavelength of abietic acid and 11-carbonyl-beta-acetyl boswellic acid is 241nm, and the absorption spectra are respectively shown in figures 1-4, which are basically consistent with the maximum absorption wavelength of the corresponding reference substances collected in the standards of Chinese pharmacopoeia and the like. When a certain fixed wavelength is adopted for detection on a high performance liquid chromatograph, other 3 components are not located at the maximum absorption wavelength, and accurate quantification cannot be carried out. On the basis of earlier research, parameters are set by combining peak separation of each component in sequence at different time periods by using a wavelength switching method, and a wavelength conversion mode that the measurement wavelength is 328nm at 0-25min, 280nm at 25-45min and 241nm at 45-70min is respectively selected for detection, so that 4 components can be detected at the maximum absorption wavelength, and the accuracy of simultaneous detection is improved.
3.2 selection of the Mobile phase
When the mobile phases are inspected, the separation effects of methanol-water, acetonitrile-water, methanol-0.1% formic acid solution and acetonitrile-0.1% formic acid solution systems are compared, and the components to be detected cannot be effectively separated by any of the four mobile phases under the condition of constant proportion. When gradient elution is carried out by adopting the elution procedure in the '2. chromatographic condition', a system using methanol-water and methanol-0.1% formic acid solution as a mobile phase has poor separation effect of 4 components and more impurity peaks; in a system using acetonitrile-water as a mobile phase, although the separation effect of abietic acid and 11-carbonyl beta-acetyl boswellic acid is relatively good, the separation effect of rhaponticin and loureirin B is relatively poor; and the system using acetonitrile-0.1% formic acid solution as mobile phase can better separate rhaponticin, loureirin B, abietic acid and 11-carbonyl-beta-acetyl boswellic acid from adjacent impurity peaks, and the separation effect is obviously better than the three mobile phases. Therefore, it was finally confirmed that gradient elution was carried out using acetonitrile-0.1% formic acid solution as a mobile phase, and under the chromatographic conditions, the chromatographic peaks were well separated and the peak shapes were good, and the chromatograms thereof were as shown in fig. 5 to 9.
3.3 optimization of extraction conditions
The kind, extraction time and solvent dosage of the extraction solvent in the method for measuring the content of the sample are optimized.
Taking 20 large Qili tablets (batch number: 200905), grinding, and taking about 0.6 g; precisely weighing, respectively and precisely adding 25mL of ethanol, methanol and 50% methanol into a conical flask, preparing the other materials according to the method of 1.2, measuring according to the chromatographic condition 2, and investigating the influence of an extraction solvent on the measurement.
Taking large seven-centimeter tablet (batch number: 200905) powder, each about 0.6g, precisely weighing, placing into a conical flask, precisely adding 10mL, 25mL and 50mL of methanol respectively, and preparing the rest according to the method of '1.2', measuring according to '2-chromatographic conditions', further examining the influence of the extraction time and the solvent dosage on the measurement, and the result shows that when the extraction time exceeds 30min and the solvent volume is more than 25mL, the content of the measured component is not increased any more. Therefore, the extraction condition for determining the content of the test sample is finally determined to be 25mL of methanol, and ultrasonic extraction is carried out for 30 min.
Example 2: method verification
1. Preparation of the Standard Curve
1.1 Rhein Standard Curve
Precisely weighing a proper amount of rhaponticin reference substance, precisely weighing, adding methanol to prepare a series of solutions containing 4.02, 8.05, 10.06, 20.12 and 33.53 mu g of rhaponticin per 1mL respectively, precisely sucking 10 mu L of the solutions respectively, injecting the solutions into a liquid chromatograph, analyzing according to the chromatographic conditions of example 1 '2', and respectively measuring the respective peak areas, wherein the sample injection amount (mu g) is used as a horizontal coordinate (X) and the peak area is used as a vertical coordinate (Y); calculating regression equation, Y =3775.5X +14.371, r2=0.9993, and the measurement results are shown in table 1.
TABLE 1 Rheum emodin Linear relationship determination results
The result shows that rhaponticin has a good linear relationship between 0.04024 and 0.3353 mu g.
1.2 Longxuejin B Standard Curve
Precisely weighing a proper amount of loureirin B reference substance, precisely weighing, adding methanol to prepare a series of solutions containing loureirin B4, 8, 10, 20 and 33.33 mu g per 1mL respectively, precisely sucking 10 mu L respectively, injecting into a liquid chromatograph, analyzing according to the 2-chromatographic condition in example 1, and respectively measuring the respective peak areas, wherein the sample injection amount (mu g) is used as a horizontal coordinate (X) and the peak area is used as a vertical coordinate (Y); calculating regression equation, Y =2571.1X +6.2706, r2=0.9993, and the measurement results are shown in table 2.
TABLE 2 determination of the Linear relationship of loureirin B
The result shows that the loureirin B has a good linear relation between 0.04 and 0.3333 mu g.
1.3 rosin acid Standard Curve
Accurately weighing a proper amount of abietic acid reference substances, accurately weighing, adding methanol to prepare 1.52, 3.04, 3.8, 7.6 and 12.67 mu g of series solutions containing abietic acid per 1mL respectively, accurately sucking 10 mu L of the solutions respectively, injecting the solutions into a liquid chromatograph, analyzing according to the chromatographic condition 2 in example 1, and respectively measuring the peak areas of the solutions, wherein the sample injection amount (mu g) is used as a horizontal coordinate (X) and the peak area is used as a vertical coordinate (Y); calculating regression equation, Y =5053.6X +3.8340, r2=0.9993, and the measurement results are shown in table 3.
TABLE 3 measurement of rosin acid linearity
The result shows that the abietic acid has a good linear relationship between 0.0152 and 0.1267 mu g.
1.411-carbonyl-beta-acetyl boswellic acid standard curve
Precisely weighing a proper amount of 11-carbonyl-beta-acetyl boswellic acid reference substances, precisely weighing, adding methanol to prepare a series of solutions containing 1.589, 3.178, 3.972, 7.944 and 13.24 mu g of 11-carbonyl-beta-acetyl boswellic acid in each 1mL respectively, precisely sucking 10 mu L of the solutions respectively, injecting the solutions into a liquid chromatograph, analyzing according to the chromatographic conditions of example 1 and 2, and respectively measuring the respective peak areas by taking the sample injection amount (mu g) as a horizontal coordinate (X) and the peak area as a vertical coordinate (Y); calculating regression equation, Y =1160.1X +0.1136, r2=0.9995, and the measurement results are shown in table 4.
TABLE 411-carbonyl-beta-acetyl boswellic acid Linear relationship assay results
The result shows that 11-carbonyl-beta-acetyl boswellic acid has good linear relation between 0.01589 and 0.1324 mu g.
2. Precision test
A mixed control solution containing 10.06. mu.g of rhaponticin, 10.0. mu.g of loureirin B, 3.8. mu.g of abietic acid and 3.972. mu.g of 11-carbonyl-beta-acetyl boswellic acid per 1mL was analyzed according to the determination method in example 1, and the sample injection was repeated 6 times, and the results are shown in Table 5.
TABLE 5 results of precision test
The result shows that the method has good precision for measuring each component in the reference substance.
3. Repeatability test
5 portions of large seven-centimeter tablets (lot No. 200905) were taken and analyzed by the method described in example 1, and the measurement was repeated 5 times, and the results are shown in Table 6.
TABLE 6 results of the repeatability tests
The result shows that the method has good repeatability for measuring each component of the sample.
4. Stability test
A mixed control solution containing 10.06. mu.g of rhaponticin, 10.0. mu.g of loureirin B, 3.8. mu.g of abietic acid and 3.972. mu.g of 11-carbonyl-beta-acetyl boswellic acid per 1mL was analyzed according to the determination method of example 1, and samples were injected at regular intervals, respectively, and the results are shown in Table 7.
TABLE 7 stability test results
The result shows that the peak areas of the four components have no obvious change within 49h, which indicates that the determination method has good stability.
5. Recovery test
By adopting a sample-adding recovery test, a large seven-centimeter tablet (batch number: 200905, rhaponticin content: 0.05613mg/g, loureirin B content: 0mg/g, abietic acid content: 0.1473mg/g, 11-carbonyl-beta-acetyl boswellic acid content: 2.3141 mg/g) with known content is precisely measured, ground, and taken 6 parts, each part is about 0.3g, and 25mL of mixed reference substance solution containing rhaponticin 0.944 mu g, loureirin B4.52 mu g, abietic acid 1.804 mu g and 11-carbonyl-beta-acetyl boswellic acid 3.388 mu g is precisely added into each 1mL, the test is carried out according to the determination method of the example 1, and the recovery rate is calculated, and the results are shown in tables 8-11.
TABLE 8 Rheum officinale recovery test results
TABLE 9 experimental results on the recovery of loureirin B
TABLE 10 rosin acid recovery test results
TABLE 1111-carbonyl-beta-acetyl boswellic acid recovery test results
The results show that the recovery rate of each component is between 98.83 and 101.69 percent, which indicates that the method has good accuracy.
6. Method detection limit
The mixed control solution prepared in example 1 was diluted to different concentrations and measured with the signal to noise ratio of 3:1 as the detection limit. The detection limits of rhaponticin, loureirin B, abietic acid and 11-carbonyl-beta-acetyl boswellic acid are respectively 0.034mg/g, 0.042mg/g, 0.026mg/g and 0.028 mg/g. Therefore, the method can detect the components with low content, has low detection limit and good effect.
Example 4: sample assay
1. Chromatographic conditions and preparation of test solution
The chromatographic conditions and the test solution preparation method are the same as those in example 1.
2. Determination of sample content
Taking 22 batches of the large seven centi preparation sample solution, performing HPLC (high performance liquid chromatography) determination, recording peak areas, and calculating the content of each component to be detected, wherein the content detection result is shown in Table 12. Wherein, the HPLC chromatogram of the sample with the batch number of 200602 is shown in figure 10, the HPLC chromatogram of the sample with the batch number of 20190601 is shown in figure 11, the HPLC chromatogram of the sample with the batch number of 191101 is shown in figure 12, and the HPLC chromatogram of the sample with the batch number of 01-200302 is shown in figure 13.
3. Result judgment
(1) In the chromatogram of the test sample, the same chromatographic peak is not obtained at the position corresponding to the retention time of the chromatographic peak of the reference solution of abietic acid, rhapontin and loureirin B. If chromatographic peaks with the same retention time appear, comparing the ultraviolet-visible absorption spectra of the corresponding chromatographic peaks by using a diode array detector, wherein the absorption spectra are different; if the absorption spectra are the same, the detection is considered positive.
(2) The content of 11-carbonyl- β -acetyl boswellic acid in the test sample should not be less than 2.0mg/g, and if less than 2.0mg/g, it is determined that the boswellic acid is not dosed according to the prescribed amount, wherein the determination results are shown in table 12.
TABLE 1222 determination of sample content and judgment (mg/g)
As can be seen from the sample detection results, the large Qili pills with the batch number of 20190601 and the large Qili loose rumex gmelin with the batch numbers of 191101, 191102 and 191104 indicate that the sample is doped with counterfeit rhubarb; detecting loureirin B from big seven li pills with the batch numbers of 20190601, 20181005 and 20190307, which indicates that the sample is mixed with dragon's blood; detecting rosin acid from large Qili pills with the batch number of 20181003 and large Qili tablets with the batch numbers of 200602 and 200905, and indicating that the samples are doped with rosin; no 11-carbonyl-beta-acetyl boswellic acid was detected in the large seven li capsules with lot numbers 01-200302, 01-200303, 01-191001, 01-191002, 01-191102 and 01-191201, indicating that no boswellic acid was added in the prescription; the 11-carbonyl-beta-acetyl boswellic acid content in the large Qili tablets with the batch number of 200602 is low, which indicates that the boswellic acid is not fed according to the prescription amount and the situation of less feeding exists. Similarly, as can be seen from FIGS. 10-13, the large Ju pian with lot number 200602 contains abietic acid, but the peak area of 11-carbonyl- β -acetyl boswellic acid is significantly smaller; the large seven li pills with the batch number of 20190601 contain rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid; the large Qili powder with the batch number of 191101 contains rhapontin and 11-carbonyl-beta-acetyl boswellic acid; the large seven li capsules with the batch number of 01-20032 do not contain rhaponticin, loureirin B, abietic acid and 11-carbonyl-beta-acetyl boswellic acid.
As for the adulterated and adulterated sample, the quality of the sample can not be completely controlled only according to the existing standard test items of the Daqili preparation, therefore, the HPLC method for simultaneously detecting abietic acid, rhapontin, lourerin B and 11-carbonyl-beta-acetyl boswellic acid in the Daqili preparation can effectively make up the defects of the existing standard test items of the Daqili preparation, solve the problem of blind spots of quality control of the Daqili preparation and provide a new detection means for powerfully striking the irregular feeding behavior of adulterated and adulterated; the detection method has the advantages of good separation effect, good repeatability of detection results, low detection limit, rapidness, accuracy, simplicity, high efficiency and low cost, and can be used as a technical means for controlling irregular feeding of the pseudo-adulteration and adulteration of the large seven centi preparations.
Finally, it should be emphasized that the above-described preferred embodiments of the present invention are merely examples of implementations, rather than limitations, and that many variations and modifications of the invention are possible to those skilled in the art, without departing from the spirit and scope of the invention.
Claims (10)
1. A method for detecting multiple components in a large seven centimetre preparation simultaneously is characterized in that an HPLC method is adopted to respectively carry out content determination and result judgment on a mixed reference solution and a test solution, octadecylsilane chemically bonded silica is used as a chromatographic column filler, acetonitrile is used as a mobile phase A, a 0.1% formic acid solution is used as a mobile phase B, gradient elution is carried out, and the number of theoretical plates is not less than 4000 according to the calculation of a rhaponticin peak; the reference solution contains abietic acid, rhaponticin, loureirin B and 11-carbonyl-beta-acetyl boswellic acid.
2. The method for simultaneously detecting multiple components in a large seven-centimeter preparation according to claim 1, wherein in the gradient elution, the volume ratio of each time period to each mobile phase is as follows:
when the time is 0-10min, the volume ratio of the mobile phase A is increased from 15% to 35%, and the volume ratio of the mobile phase B is decreased from 85% to 65%;
when the time is 10-30min, the volume ratio of the mobile phase A is increased from 35% to 50%, and the volume ratio of the mobile phase B is decreased from 65% to 50%;
when the time is 30-55min, the volume ratio of the mobile phase A is increased from 50% to 90%, and the volume ratio of the mobile phase B is decreased from 50% to 10%;
when the time is 55-70min, the volume ratio of the mobile phase A is 90%, and the volume ratio of the mobile phase B is 10%.
3. The method for simultaneously detecting multiple components in a large seven-centimeter preparation according to claim 1, wherein the detection wavelength of HPLC is a segment wavelength, and the segment wavelength is converted by: at 0-25min, the wavelength is 328 nm; the wavelength is 280nm when the time is 25-45 min; the wavelength is 241nm at 45-70 min.
4. The method for simultaneously detecting multiple components in a large seven centimetre formulation according to claim 1, wherein the method for determining the result comprises: (1) in the chromatogram of the test solution, the same chromatographic peak is not obtained at the position corresponding to the retention time of the chromatographic peak of the reference solution of abietic acid, rhapontin and lourerin B, and when the chromatographic peak with the same retention time is obtained, a diode array detector is adopted to compare the ultraviolet-visible absorption spectra of the corresponding chromatographic peak, and the absorption spectra are different; when the absorption spectra are the same, the detection result is regarded as positive detection; (2) the content of 11-carbonyl-beta-acetyl boswellic acid in the test solution is not less than 2.0mg/g, and when the detection result is less than 2.0mg/g, the boswellia is regarded as being not fed according to the prescription amount.
5. The method as claimed in claim 1, wherein the method for preparing the mixed reference solution comprises precisely weighing appropriate amounts of abietic acid, rhapontin, loureirin B and 11-carbonyl- β -acetyl boswellic acid, adding methanol into a volumetric flask, and making into a mixed solution containing abietic acid, rhapontin, loureirin B and 11-carbonyl- β -acetyl boswellic acid.
6. The method as claimed in claim 1, wherein the preparation method of the test solution comprises precisely weighing appropriate amount of pulverized and mixed large QILI preparation sample, placing in conical flask with plug, adding methanol solution, sealing, weighing, ultrasonically treating for 30min, taking out, cooling, weighing again, adding methanol solution to make up for the lost weight, shaking, and filtering to obtain filtrate as test solution.
7. The method for simultaneously detecting multiple components in a seven centimeter formulation according to claim 6, wherein the sonication power is 500W and the frequency is 40 kHz.
8. The method for simultaneously detecting multiple components in a large seven centimetre formulation according to claim 1, wherein the abietic acid, rhapontin and loureirin B are derived from non-standardized feeds, and the 11-carbonyl- β -acetyl boswellic acid is the prescribed component in the large seven centimetre formulation.
9. The method for simultaneously detecting multiple components in a large seven li preparation according to claim 1, wherein the large seven li preparation is any one of a large seven li tablet, a large seven li pill, a large seven li capsule and a large seven li powder.
10. Use of the method for simultaneous detection of multiple components in a large seven-centimeter preparation according to any one of claims 1 to 9 in the quality detection of large seven-centimeter preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210194754.XA CN114252548B (en) | 2022-03-02 | 2022-03-02 | Method for simultaneously detecting multiple components in large seven-li preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210194754.XA CN114252548B (en) | 2022-03-02 | 2022-03-02 | Method for simultaneously detecting multiple components in large seven-li preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114252548A true CN114252548A (en) | 2022-03-29 |
| CN114252548B CN114252548B (en) | 2022-05-31 |
Family
ID=80800151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210194754.XA Active CN114252548B (en) | 2022-03-02 | 2022-03-02 | Method for simultaneously detecting multiple components in large seven-li preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114252548B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999000114A2 (en) * | 1997-06-26 | 1999-01-07 | Statens Serum Institut | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
| CN101411833A (en) * | 2008-12-12 | 2009-04-22 | 北京理工亘元医药技术开发中心有限公司 | Dragon's blood extract as well as preparation method and application thereof |
| WO2011076196A1 (en) * | 2009-12-22 | 2011-06-30 | Cardionovum Sp.Z.O.O. | Frankincense and boswellic acids as a coating for stents and catheter balloons |
| CN104007187A (en) * | 2013-02-27 | 2014-08-27 | 湖南天地恒一制药有限公司 | Detection method for safflower-qili capsule |
| CN109307721A (en) * | 2018-10-26 | 2019-02-05 | 陕西步长制药有限公司 | A kind of HPLC-QQQ/MS method measures the detection method of content of effective component in Dragon groundnut |
-
2022
- 2022-03-02 CN CN202210194754.XA patent/CN114252548B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999000114A2 (en) * | 1997-06-26 | 1999-01-07 | Statens Serum Institut | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
| CN101411833A (en) * | 2008-12-12 | 2009-04-22 | 北京理工亘元医药技术开发中心有限公司 | Dragon's blood extract as well as preparation method and application thereof |
| WO2011076196A1 (en) * | 2009-12-22 | 2011-06-30 | Cardionovum Sp.Z.O.O. | Frankincense and boswellic acids as a coating for stents and catheter balloons |
| CN104007187A (en) * | 2013-02-27 | 2014-08-27 | 湖南天地恒一制药有限公司 | Detection method for safflower-qili capsule |
| CN109307721A (en) * | 2018-10-26 | 2019-02-05 | 陕西步长制药有限公司 | A kind of HPLC-QQQ/MS method measures the detection method of content of effective component in Dragon groundnut |
Non-Patent Citations (11)
| Title |
|---|
| HAIYAN ZHAO 等: "An HPLC-ESI-MS method for analysis of loureirin A and B in dragon"s blood and application in pharmacokinetics and tissue distribution in rats", 《FITOTERAPIA》, 31 December 2013 (2013-12-31), pages 149 - 158 * |
| 张英姿等: "HPLC法在接骨七厘片龙血素B含量测定中的应用", 《辽宁中医杂志》 * |
| 张英姿等: "HPLC法在接骨七厘片龙血素B含量测定中的应用", 《辽宁中医杂志》, no. 06, 18 June 2019 (2019-06-18), pages 1259 - 1261 * |
| 杨俊龙等: "辽源七厘复方中药控释微丸制备工艺研究", 《中国医院用药评价与分析》 * |
| 杨俊龙等: "辽源七厘复方中药控释微丸制备工艺研究", 《中国医院用药评价与分析》, no. 11, 30 November 2016 (2016-11-30), pages 1469 - 1471 * |
| 王瑞忠 等: "HPLC法测定冠脉宁片(胶囊)中11-羰基-β-乙酰乳香酸及松香酸检查", 《中成药》 * |
| 王瑞忠 等: "HPLC法测定冠脉宁片(胶囊)中11-羰基-β-乙酰乳香酸及松香酸检查", 《中成药》, vol. 36, no. 11, 30 November 2014 (2014-11-30), pages 2326 - 2329 * |
| 王瑞忠等: "西黄丸中11-羰基-β-乙酰乳香酸含量测定及松香酸检查方法研究", 《中国药事》 * |
| 王瑞忠等: "西黄丸中11-羰基-β-乙酰乳香酸含量测定及松香酸检查方法研究", 《中国药事》, no. 04, 20 April 2013 (2013-04-20), pages 389 - 393 * |
| 王璐等: "超高效液相色谱-串联质谱法同时测定中药制剂中松香酸、11-羰基-β-乙酰乳香酸及苏丹红Ⅰ~Ⅳ的含量", 《分析测试学报》 * |
| 王璐等: "超高效液相色谱-串联质谱法同时测定中药制剂中松香酸、11-羰基-β-乙酰乳香酸及苏丹红Ⅰ~Ⅳ的含量", 《分析测试学报》, no. 05, 18 May 2016 (2016-05-18), pages 526 - 531 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114252548B (en) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023024322A1 (en) | Method for determining fingerprint of traditional chinese medicine composition | |
| CN102854258B (en) | Chemical characteristic analysis for detecting quinone, stilbene, flavonoid and alkaloid composition | |
| CN108445125B (en) | HPLC Fingerprint Detection Method for Zhitong Huazheng Capsules | |
| CN110763793A (en) | Method for detecting active ingredients of salvia miltiorrhiza and products | |
| CN100437112C (en) | Method for inspecting Chinese medicinal preparation quality in treatment of old man eyes dieases | |
| CN102749299A (en) | Quality detection method of traditional Chinese medicine composition medlar thirst quenching preparation | |
| CN105486790B (en) | The fingerprint atlas detection method of Shenshuaining particle | |
| CN109668970B (en) | Ultra-high performance liquid chromatography detection method for traditional Chinese medicine composition | |
| CN102441057B (en) | High performance liquid chromatography (HPLC) fingerprint detection method for blood-nourishing brain-refreshing grain | |
| CN104502485B (en) | The quantitative analysis method of 6 chemical compositions in the compound Chinese medicinal preparation that is medicinal material by rhizoma dioscoreae nipponicae and wilsonii | |
| CN103969360B (en) | The detection method of Ligusticum wallichii | |
| CN102397517A (en) | Quality control method of Tibetan lipid-lowering preparation | |
| CN114252548B (en) | Method for simultaneously detecting multiple components in large seven-li preparation | |
| CN105424833A (en) | Component test method of FKIV granules | |
| CN113655166A (en) | High performance liquid detection method for 14 components in golden flower refreshing granules | |
| CN113341007A (en) | Method for measuring contents of multiple components in whole Chinese date seed nerve-soothing capsule based on HPLC (high performance liquid chromatography) characteristic spectrum | |
| CN113640432A (en) | Quality evaluation method of loins strengthening and body building pills | |
| CN112268968B (en) | Detection method of fingerprint spectrum of medicinal preparation | |
| CN108982731B (en) | Method for constructing HPLC characteristic spectrum of sarcandra glabra buccal tablet and HPLC characteristic spectrum thereof | |
| CN113759056B (en) | Characteristic spectrum of Chinese lobelia and preparation thereof and construction method thereof | |
| CN105301140B (en) | A kind of injection component detection method promoting blood circulation and removing obstruction in channels | |
| CN115856181A (en) | Characteristic spectrum of linseed decoction pieces and preparation thereof as well as construction method and application of characteristic spectrum | |
| CN111562324B (en) | Method for detecting contents of multiple index components of breast-eliminating and stasis-removing capsule | |
| CN115575546A (en) | Construction method and content determination method of HPLC (high Performance liquid chromatography) fingerprint spectrum of Wuzi Yanzong soft capsule | |
| CN103575823A (en) | Detection method of 8 chemical components in Tangminling preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |